Product Description
| Download Documents | |
| SDS | USER MANUAL will be supplied to customer |
AqT® Biotin Site-Specific Antibody Labeling kit is a proprietary biotinylation kit developed at CellMosaic® for obtaining high quality and Fc-region biotinylated antibodies with minimal or no aggregation.
For a detailed description of the AqT® technologies, please see our technology section.
The kit is available in multiple configurations for labeling antibodies (0.1-3 mg) with either one (x1) or three (x3) antibody samples.
|
Catalog Number |
Number of Reactions in Kit |
Antibody Amount per Reaction |
| CM86141.01x1 | 1 | 100 μg (0.667 nmol for IgG) |
| CM86141.01x3 | 3 | |
| CM86141.1x1 | 1 | 0.1-1 mg (0.667-6.67 nmol for IgG) |
| CM86141.1x3 | 3 | |
| CM86141x1 | 1 | 1-3 mg (6.67-20 nmol for IgG) |
| CM86141x3 | 3 |
If you have any other customization needs, please provide the details above.
Requirement for Antibody
- MW: ≥ 100 KDa (if MW is lower, please use an alternative kit)
- Preferably >90% pure by gel electrophoresis
- Total amount: 0.1-3 mg of protein content as measured by UV.
Key Features of CM86141 Compared with Typical Commercial Biotin Labeling Kits
AqT® technology enables site-specific biotinylation at reduced Fc-region disulfide bonds, preserving antigen-binding activity while producing more homogeneous, stable, and less aggregation-prone biotinylated antibodies. Compared with conventional antibody biotinylation methods, AqT® biotinylation minimizes changes to antibody properties and provides more consistent labeling results.
|
Category |
AqT® Biotin Labeling Kit |
Typical Commercial Biotin Labeling Kits |
|
Labeling Strategy |
Site-specific Fc labeling · Labels reduced Fc-region disulfide bonds (away from the antigen-binding region) · Preserves antibody binding activity and orientation |
Random surface amine labeling · Typically targets lysine residues · Labeling may occur near or within the Fab region · May reduce antibody binding activity |
|
Product Homogeneity |
More homogeneous product with consistent biotin incorporation |
Heterogeneous mixture of differently labeled antibody species |
|
Antibody Properties After Labeling |
Retains native antibody properties · No significant increase in hydrophobicity · No significant increase in apparent MW · Minimal aggregation |
May alter antibody properties · Increased hydrophobicity · Increased apparent MW · Increased risk of aggregation |
|
Linker Technology |
Proprietary AqT® super-hydrophilic, water-soluble, charge-neutral linker |
Zero length biotin or biotin with hydrophobic ethylene- or polyethylene glycol-type linkers |
|
Biotin Loading |
Predictable and consistent · Typical 3–5 biotin molecules per antibody (average » 4) |
Less predictable · Labeling efficiency may vary with reagent quality and storage conditions |
|
Stability of Labeled Antibody |
Excellent Stability · Can be stored frozen or lyophilized without any stabilizers |
High biotin loading may increase aggregation and precipitation |
|
Ease of Use |
Simple Workflow · Complete protocol within ~4 hours · <2 hours hands-on time |
Some rapid-labeling chemistries (e.g., EDC-mediated coupling) may crosslinkantibodies, resulting in large aggregates |
|
Purification components |
Included |
Varies by vendor; often not included |
|
Biotin Assay |
Includes a 10-minute biotin assay protocol with reagents |
Typically not included |
Applications and Advantageous of Site-Specific AqT® Biotinylated Antibodies
Labeling Chemistry
Protocol
Schematic workflow diagram for preparing AqT® biotin site-specific labeled antibody within 24 hours, starting with 3 mg of IgG. (Reagent volume will vary if the amount of IgG is less than 3 mg).
Example Data
The figures below show examples of AqT® biotin site-specific labeled antibodies compared with conventionally biotinylated antibodies. The extent of labeling and the heterogeneity of the labeled antibodies were assessed by hydrophobic interaction chromatography (HIC)-HPLC (Figure 1). Apparent molecular weight and aggregation were evaluated by size-exclusion chromatography (SEC)-HPLC (Figure 2).
Figure 1: Overlay of HIC HPLC profiles of unlabeled antibody (Trastuzumab), Biotin-PEG2 antibody (DOL: 5.2), Biotin-BMCC antibody (DOL: 6.2), AqT® Biotin antibody (DOL: 4.6), and AqT® Biotin antibody (DOL: 6.7).
Figure 2: Overlay of SEC-HPLC chromatograms of the unlabeled antibody (transtuzumab) and AqT® biotin antibody (DOL: 4.6).
AqT® biotinylated trastuzumab show little to no shift in apparent molecular weight and exhibit a hydrodynamic volume similar to that of the native trastuzumab, with no detectable aggregation
Frequently Asked Questions:
If you can’t find the answer you’re looking for or need information on general topics, please visit the main Frequently Asked Questions (FAQs) section.
Other Details
The information in this document is subject to change without notice. CellMosaic® assumes no responsibility for any errors or omissions that may appear in this document. Under no circumstances shall CellMosaic be liable, whether in contract, tort, warranty, or under any statute or on other legal theory, for special, incidental, indirect, punitive, multiple, or consequential damages related to or arising from this document, including but not limited to the use of this product thereof.CellMosaic’s products, including but not limited to AqT®, NeIon™, oxLink™ and sxLink™ (collectively, the “Products”), are covered by, or are the subject of, one or more issued patents and pending patent applications, including without limitation: 9,688,663 B2; 8,907,079 B2; 9,511,150 B2; 9,907,854 B2; 9,346,833 B2; 9,518,067 B2; CN104066451B; CN107043339B; CA 2,841,313; EP 2734238 B1; AU2012284055; JP 6240599 B2; and corresponding foreign patents and patent applications. The purchase of the Product conveys solely a limited, non-exclusive, non-transferable, non-sublicensable license to use the Product only for the purchaser’s internal research and development purposes. No right or license is granted, either expressly or by implication, estoppel, or otherwise, under any patent, trademark, copyright, or other intellectual property right of CellMosaic, except as expressly stated herein. Any commercial use of the Product is strictly prohibited without a separate written agreement from CellMosaic. Prohibited commercial uses include, without limitation: (a) the sale, lease, licensing, distribution, or other transfer of the Product or any materials derived from or produced using the Product; (b) the sale, lease, licensing, or other grant of rights to use the Product or any materials derived from or produced using the Product; and (c) the use of the Product to perform services for a fee or other consideration for third parties, including without limitation contract research, screening services, or diagnostic or therapeutic applications. For information regarding commercial licensing or collaboration, please contact us at info@cellmosaic.com.
